V-wave Limited

The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Other

Tel Aviv University

Angiodynamics, Inc.

Flowmedica, Inc.

Hemodynamx-technologies Ltd.

Gad Keren

Ascher Shmulewitz

Randy J Kesten

Dan Rottenberg

Ori J Braun

Yoram Rozy

Avraham Aba Zakay

Michael H Rosenthal

Benjamin Spenser

Michael Arad

Sam G Payne

Sophia Pesotchinsky

Andrew W Kramer

Jacob George

Yoel Kloog

Allan C Entis

Jakob George

Avraham Aba Sakay

A differential pressure regulating device is provided for controlling in-vivo pressure in a body, particular in a heart. The device may include a shunt being positioned between two or more lumens in a body, to enable fluids to flow between the lumens, and an adjustable flow regulation mechanism being configured to selectively cover an opening of the shunt to regulate the flow of fluid through the shunt in relation to a pressure difference between the body lumens. In some embodiments, a control mechanism coupled to the adjustable flow regulation mechanism may be provided to remotely activate the adjustable flow regulation mechanism.

Device and method for controlling in-vivo pressure

A differential pressure regulating device is provided for controlling in-vivo pressure in a body, and in particularly in a heart. The device may include a shunt being positioned between two or more lumens in a body, to enable fluids to flow between the lumens, and an adjustable flow regulation mechanism being configured to selectively cover an opening of the shunt, to regulate the flow of fluid through the shunt in relation to a pressure difference between the body lumens. In some embodiments a control mechanism coupled to the adjustable flow regulation mechanism may be provided, to remotely activate the adjustable flow regulation mechanism.

Described embodiments include apparatus () that includes a shunt (). The shunt includes a flared distal portion (), a flared proximal portion (), and an intermediate portion (), disposed between the distal portion and the proximal portion. The apparatus further includes a constricting flexible longitudinal element () passing circumferentially along the intermediate portion of the shunt, configured to constrict the intermediate portion of the shunt, and one or more proximal-portion-collapsing flexible longitudinal elements () configured to collapse the proximal portion of the shunt. Other embodiments are also described.

Temporary interatrial shunts

A brace for mounting to an annulus of a cardiac valve, the brace comprising: first and second bottom gripping wings for gripping the annulus; first and second top gripping wings for gripping the annulus; and a support bridge that connects the top wings to the bottom wings; wherein the brace is deformable from a delivery configuration to a deployed configuration and in the delivery configuration the top wings are oriented substantially back to back along an axis and the bottom wings are oriented substantially back to back along the same axis, and in the deployed configuration the first top and bottom gripping wings face each other to grip the annulus between them and the second top and bottom gripping wings face each other to grip the annulus between them.

Cardiac valve commissure brace

A differential pressure regulating device is provided for controlling in-vivo pressure in body, and in particularly in a heart. The device may include a shunt being positioned between two or more lumens in a body, to enable fluids to flow between the lumens, and an adjustable flow regulation mechanism being configured to selectively cover an opening of the shunt, to regulate the flow of fluid through the shunt in relation to a pressure difference between the body lumens. In some embodiments a control mechanism coupled to the adjustable flow regulation mechanism may be provided, to remotely activate the adjustable flow regulation mechanism.

A method of replacing a native cardiac valve with a prosthetic cardiac valve, the method comprising: expanding a wire mesh scaffolding in a chamber of the heart on a retrograde side of the native cardiac valve; while the scaffolding is expanded on the retrograde side of the valve positioning the prosthetic cardiac valve at the site of the native cardiac valve; expanding the prosthetic cardiac valve to replace the native cardiac valve; and collapsing the scaffolding to a collapsed state and removing the collapsed scaffolding from the chamber of the heart.

Cardiac prostheses and their deployment

The present invention is thus directed to methods and apparatus for decreasing pressure in a first portion of a vessel of the cardiac structure of a patient by implanting a shunt communicating with an area outside said first portion, whereby a volume of blood sufficient to reduce pressure in said first portion is released.

Methods and apparatus for reducing localized circulatory system pressure

The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. Also provided are specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing such antibodies.

Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders

The present invention is thus directed to methods and apparatus for decreasing pressure in a first portion of a vessel of the cardiac structure of a patient by implanting a shunt communicating with an area outside said first portion, whereby a volume of blood sufficient to reduce pressure in said first portion is released. Preferably, the first portion comprises the left ventricle and the pressure reduced is the end diastolic pressure, which is accomplished by having the shunt communicate with the left ventricle so a small volume of blood is released from the left ventricle to reduce the end diastolic pressure. Most preferably, the shunt selectively permits flow when a pressure differential between the left ventricle and another chamber of a heart above a threshold pressure, whereby shunting is prevented during left ventricular systole, or, alternatively, selectively permits flow when a pressure differential between the left ventricle and another chamber of a heart is between a lower threshold and a higher threshold, whereby shunting is again prevented during left ventricular systole. In certain embodiments a semi-passive check-valve is controlled and actuated by an external signal, either using a signal generated by an intra-corporeal electrical battery or an externally coupled energy source. In certain embodiments, the shunt has a pump with an input connected to the left ventricle, or other portion with excessive pressure, and an output connected to a volume of lower pressure. The preferred method of implanting the shunt to effect the present invention is by deploying a tubular element having two ends and a tissue affixation element disposed at each of said ends via a catheter, preferably, the fixation element is a shape retaining metallic material that returns to its original shape as part of the retention aspect of its function. In preferred embodiments of the apparatus, the tubular element is comprised of a biologically inert non-metallic material.

Growing community of inventors

Kiryat Ono, Israel

Gad Keren